Q-omics provides the consensus-scored ST3GAL2 profile across patient tissues and cancer cell-line models. ST3GAL2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ST3GAL2 is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, ST3GAL2 RNA expression shows 19,765 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where ST3GAL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST3GAL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST3GAL2 survival associations across molecular data types. ST3GAL2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST3GAL2 RNA expression–survival associations across cancer types. High ST3GAL2 expression shows unfavorable associations in MESO, KIRP, ACC, LUSC and LIHC, but favorable associations in PAAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ST3GAL2 RNA expression.
This table summarizes ST3GAL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ST3GAL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST3GAL2 shows higher tumor expression in HNSC, COAD, KIRC, LIHC, STAD and KIRP. The HNSC box plot shows higher ST3GAL2 RNA expression in tumor versus normal tissue (log2 FC = +1.336, t-test p < 0.001).
This table shows molecular features associated with ST3GAL2 in patient tissues and cancer cell lines. In patient samples, ST3GAL2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ST3GAL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
